Effects of calcium antagonists on serotonin-dependent aggregation and serotonin transport in platelets of patients with migraine

  title={Effects of calcium antagonists on serotonin-dependent aggregation and serotonin transport in platelets of patients with migraine},
  author={T. G. Pukhal'skaya and Olga A. Kolosova and M. Yu. Men’shikov and A. M. Vein},
  journal={Bulletin of Experimental Biology and Medicine},
Flunarizine and cinnarizine (IC50 6.8×10−6 and 2.8×10−5 M, respectively) inhibited3H-serotonin uptake by platelets. In higher doses, they blocked serotonin-induced platelet aggregation and stimulated3H-serotonin release from these cells. Imipramine did not affect serotonin-releasing effects of preparations. In all patients cinnarizine was more potent in inhibiting serotonin uptake, and in half of the patients cinnarizine displayed higher activity as an inductor of serotonin release. 
Flunarizine is a Highly Potent Inhibitor of Cardiac hERG Potassium Current
The effects of flunarizine on potassium currents through cardiac channels encoded by the human ether-a-go-go related gene (hERG) stably expressed in CHO cells are examined with standard whole-cell voltage-clamp techniques.
Episodic Spontaneous Hypothermia Potentially Triggered by Hyperinsulinemia
Treatment with flunarizine, a drug considered the first line in the treatment of migraine-related disorders, was started with a resulting reduction in the episodes and hyperinsulinemia is suggested as a potential mechanism for episodic spontaneous hypothermia.
Cinnarizine- and flunarizine-associated movement disorder: a literature review
  • J. Rissardo, A. Caprara
  • Medicine, Psychology
    The Egyptian Journal of Neurology, Psychiatry and Neurosurgery
  • 2020
Parkinsonism was the most well described MD and myoclonus was the poorest described MD with missing data about the neurological examination and electrodiagnostic studies.
Flunarizine for the prevention of migraine
The evidence from randomized controlled trials on the effectiveness and tolerability of flunarizine for preventing migraine attacks in adults is described and assessed.
Recent Advances in Delivery Systems and Therapeutics of Cinnarizine: A Poorly Water Soluble Drug with Absorption Window in Stomach
The paper provides insight to the approaches to overcome low and erratic bioavailability of cinnarizine by cyclodextrin complexes and novel dosage forms: self-nanoemulsifying systems and buoyant microparticulates.


Migraine, Serum Serotonin and Platelet 5–HT2 Receptors
It is verified that migraine with aura differs biochemically from migraine without aura.
Effects of some calcium antagonists on aggregation by adrenalin and serotonin and on alpha-adrenoceptor radioligand binding in human platelets.
The results suggest that verapamil at high concentrations not only has alpha-adrenoceptor antagonistic properties but also exerts 5-HT-receptor blocking effects.
Decreased platelet 3H-imipramine binding sites in classical migraine.
Patients with classical migraine investigated between attacks had significantly fewer platelet 3H-imipramine binding sites than control subjects and this finding was more marked in males than in
Effect of Calcium Channel Blockers on Serotonin Uptake
  • N. Hill, S. L. Lee, B. Fanburg
  • Biology, Medicine
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine
  • 1990
It is concluded that inhibition of serotonin uptake by verapamil is a generalized phenomenon, occurring in a variety of cell types, in intact organs, and in different species that does not occur consistently with other calcium channel blockers.
The 5-hydroxytryptamine system of blood platelets: physiology and pathophysiology.
  • A. Pletscher
  • Biology, Medicine
    International journal of cardiology
  • 1987
Identification of nonserotonergic [3H]ketanserin binding sites associated with nerve terminals in rat brain and with platelets; relation with release of biogenic amine metabolites induced by ketanserin- and tetrabenazine-like drugs.
It was concluded that nonserotonergic ketanserin sites mediate release of oxidated metabolites of biogenic amines from nerve endings and of serotonin from platelets, which is probably not a mere diffusion process but involves specific membranous molecules.